Stocks and Investing
Stocks and Investing
Fri, August 5, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, August 4, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (ALNY) at Hold with Increased Target to $225 on, Aug 4th, 2022
Matthew Harrison of Morgan Stanley, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Hold with Increased Target from $159 to $225 on, Aug 4th, 2022.
Matthew has made no other calls on ALNY in the last 4 months.
There are 6 other peers that have a rating on ALNY. Out of the 6 peers that are also analyzing ALNY, 4 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Lebowitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $164 on, Friday, July 15th, 2022
- Olivia Brayer of "Cantor Fitzgerald" Initiated at Hold and Held Target at $175 on, Wednesday, July 13th, 2022
- Debjit Chattopadhyay of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, June 27th, 2022
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $98 on, Wednesday, June 15th, 2022
These are the ratings of the 2 analyists that currently disagree with Matthew
- Myles Minter of "William Blair" Initiated at Buy on, Tuesday, June 7th, 2022
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $430 on, Monday, May 2nd, 2022
Contributing Sources